ArticleIndian journal of ophthalmology2026
Evaluation of iStent® Inject W in mild to moderate primary open-angle glaucoma - Indian data on pseudophakic eyes.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the safety and efficacy of standalone bilateral iStent® Inject W implantation in pseudophakic patients with mild to moderate primary open-angle glaucoma (POAG) over 18 months.
designProspective, longitudinal study.
methodsTwenty-eight pseudophakic eyes with mild to moderate POAG were implanted with iStent® Inject W. Outcome measures included intraocular pressure (IOP) and change in the number of antiglaucoma medications.
resultsThe mean IOP declined from 21.14 ± 2.18 mmHg preoperatively to 15.14 ± 1.51 mmHg at 18 months postoperatively ( P < 0.0001), while the average number of antiglaucoma medications was reduced from 2.07 ± 0.73 to 1.18 ± 0.83 over the same period ( P < 0.05).
conclusionStandalone iStent® Inject W implantation in pseudophakic patients with mild to moderate POAG results in a sustained reduction in IOP and the number of antiglaucoma medications at 18 months postoperatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.